Giardia lamblia is a protozoan pathogen that colonizes the gastrointestinal tract and results in giardiasis. Recently, researchers from the University of California San Diego aimed to identify potent proteasome inhibitors that selectively target G. lamblia, as potential antigiardiasis therapeutics with low toxicity.
The HIV journey is a roller coaster of highs and lows for the patients living with HIV and their families and loved ones but also for the community of researchers and clinicians who pour their hearts and souls into the work they do, said speakers at the International AIDS Society (IAS) 2023 conference in Brisbane, Australia.
Bacteria cells are masters of adaptation and evolution, and by better understanding how they adapt and evolve, researchers hope to develop better drugs to fight microbial resistance, which is increasingly becoming a global public health threat. Researchers from the antimicrobial resistance interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART) sought to understand the mechanisms bacteria use to adapt against stressors, and they discovered a new stress signaling system that sheds light on a new mechanism of antimicrobial resistance.
Vir Biotechnology Inc. said it won’t be discussing further the phase II data from the influenza A prevention study called Peninsula until the company’s second-quarter earnings update Aug. 3, and a closer look at the results has yet to decide the fate of monoclonal antibody VIR-2482, which missed its primary and secondary endpoints.
T2 Biosystems Inc. received a third FDA breakthrough device designation with its direct-from-blood molecular diagnostic test for Candida auris. The test joins its T2resistance panel and T2Lyme panel in gaining the breakthrough recognition and the increased access to the FDA that comes with it as the company seeks final approval or clearance. The C. auris test enables identification of the challenging pathogen in three to five hours instead of the several days often required to grow a culture traditionally.
The most in-depth study to date of the genetic risk factors for long COVID has identified 73 genes that are highly associated with severe or fatigue-dominant forms of the disease. Many of these genes also are known to be associated with other disorders, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and neurodegenerative, autoimmune, cardiovascular and metabolic diseases.
Since its emergence in late 2019, SARS-CoV-2 has killed nearly 7 million people. But at the same time, many infections, in particular in children and young adults, are asymptomatic with rapid viral clearance from the body. It remains unclear why many individuals are able to successfully clear infection without major complications while others develop severe disease, even without known risk factors for severe COVID-19 outcomes.
Now, a new study involving nearly 30,000 individuals has found that variation in the human leukocyte antigen (HLA) loci may underlie processes mediating asymptomatic infection. The findings were reported in the July 19, 2023, online edition of Nature.